前列地尔联合胰激肽原酶治疗早期糖尿病足患者的临床效果分析

Clinical Effect Analysis of Alprostadil Combined with Pancreatic Kininogenase in Patients with Early Diabetic Foot

目的分析前列地尔联合胰激肽原酶治疗早期糖尿病足患者的临床效果。方法选择2017年5月—2018年5月该院收治的70例早期糖尿病足患者,随机分为对照组和观察组,对照组予以常规治疗,观察组给予前列地尔联合胰激肽原酶治疗,比较两组的治疗效果、治疗前后的足背动脉、踝肱指数情况。结果对照组的总有效率77.14%明显低于对照组94.28%,差异有统计学意义(P<0.05),同时观察组的足背动脉及踝肱指数的改善幅度优于对照组,差异有统计学意义(P<0.05)。结论早期糖尿病足患者应用前列地尔联合胰激肽原酶治疗的效果显著,可改善足背动脉、踝肱指数等相关指标,值得临床推广应用。

Objective To analyze the clinical effect of alprostadil combined with kallikrein in the treatment of early diabetic foot. Methods Seventy patients with early diabetic foot admitted to our hospital from May 2017 to May 2018 were randomly divided into the control group and the observation group. The control group received routine treatment. The observation group was given alprostadil plus pancreatic kininogenase. Treatment, comparing the treatment effect of the two groups, the dorsal artery of the foot before and after treatment, and the sputum index. Results The total effective rate of the control group was 77.14%, which was significantly lower than that of the control group(94.28%),the difference was statistically signficant(P<0.05). The improvement of the dorsal artery and sputum index in the observation group was better than that of the control group,the difference was statistically signficant(P<0.05). Conclusion The effect of alprostadil combined with pancreatic kininogenase in patients with early diabetic foot is significant, which can improve the related indexes of dorsal artery and tendon index, which is worthy of clinical application.